Reasons for the Failure of Platelet Function Testing to Adjust Antiplatelet Therapy
International audience In the ARCTIC trial (Assessment by a Double Randomization of a Conventional Antiplatelet Strategy Versus a Monitoring-Guided Strategy for Drug-Eluting Stent Implantation and of Treatment Interruption Versus Continuation One Year After Stenting), treatment adjustment following...
Published in: | Circulation: Cardiovascular Interventions |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , |
Other Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
HAL CCSD
2019
|
Subjects: | |
Online Access: | https://hal.science/hal-02869075 https://doi.org/10.1161/CIRCINTERVENTIONS.118.007749 |
Summary: | International audience In the ARCTIC trial (Assessment by a Double Randomization of a Conventional Antiplatelet Strategy Versus a Monitoring-Guided Strategy for Drug-Eluting Stent Implantation and of Treatment Interruption Versus Continuation One Year After Stenting), treatment adjustment following platelet function testing failed to improve clinical outcomes. However, high-on-treatment platelet reactivity (HPR) is considered as a predictor of poor ischemic outcome. This prespecified substudy evaluated clinical outcomes according to the residual platelet reactivity status after antiplatelet therapy adjustment. URL: https://www.clinicaltrials.gov. Unique identifier: NCT00827411. |
---|